Book a demo
Skip to content

Stonewake Monitoring

TuHura Biosciences files 8-K disclosing a debt obligation

The Nasdaq-listed pharmaceutical company filed an 8-K on September 4, 2026, its second debt-related filing in under a month.

Export financeUSAPublished · 3 sourced facts

TuHura Biosciences, Inc./NV, a Nevada-incorporated pharmaceutical preparations company trading on Nasdaq under the ticker HURA, filed an 8-K on September 4, 2026.[1][2]

The filing, dated for a period ending September 2, 2026, reports a debt obligation under Item 2.03 and includes Item 9.01, with accession number 0001193125-26-383797.[1]

It follows an earlier 8-K filed on August 21, 2026, which also reported a debt obligation under accession number 0001193125-26-361272.[3]

Sources

  1. [1]SEC EDGAR: 8-K, 0001193125-26-383797, 4 Sep 2026
  2. [2]SEC EDGAR: CIK 0001498382, TuHURA Biosciences, Inc./NV
  3. [3]SEC EDGAR: 8-K, 0001193125-26-361272, 21 Aug 2026

SEC EDGAR

← All briefs